India to Tanzania: Amino Export Trade Route

All pharmaceutical products intended for importation must be registered with TMDA. The registration process involves submitting a comprehensive dossier that adheres to the Common Technical Document (CTD) format. This dossier should include detailed information on the product's quality, safety, and efficacy. Additionally, importers are required to register their premises with TMDA and obtain the necessary business permits. Applications for import permits must be submitted at least six weeks prior to loading the consignment to avoid storage costs at ports of entry and potential disposal costs for unpermitted products. The remaining shelf-life of the product should be at least 60% for products with a shelf-life greater than 24 months, and at least 80% for products with a shelf-life less than 24 months. (tmda.go.tz)

Indian manufacturers exporting Amino formulations to Tanzania must comply with Good Manufacturing Practices (GMP) as stipulated by TMDA. TMDA conducts inspections of manufacturing facilities to verify compliance with GMP standards. Manufacturers are required to submit a Site Master File as part of the registration process, detailing their manufacturing practices and quality control measures. TMDA maintains a list of GMP-compliant facilities, and only products from these facilities are permitted for importation. As of March 2026, there have been no public reports of TMDA taking regulatory actions against Indian pharmaceutical companies exporting to Tanzania. (tmda.go.tz)

In the past 18 months, TMDA has implemented several regulatory changes to enhance the quality and safety of imported pharmaceutical products. In January 2025, TMDA introduced an online portal for the submission of import permit applications, streamlining the process and reducing approval times to seven days. In June 2025, TMDA updated its guidelines to require that all imported pharmaceutical products include labeling in both English and Swahili, ensuring better comprehension among healthcare providers and patients. Additionally, in September 2025, TMDA signed a mutual recognition agreement with the Indian Central Drugs Standard Control Organization (CDSCO), facilitating faster approval processes for Indian-manufactured pharmaceutical products that have already been approved by CDSCO.

TARIFF_NOTES: Pharmaceutical products, including finished formulations under HS code 30049099, are exempt from import duties in Tanzania.

As of 2025, Tanzania's pharmaceutical market is valued at approximately $1.5 billion, with an annual growth rate of 10%. The demand for amino acid formulations is primarily driven by the prevalence of malnutrition, chronic diseases, and the need for nutritional supplements. In 2024, Tanzania imported finished pharmaceutical formulations containing amino acids worth $3.7 million from India, accounting for 1.1% of India's total exports of such products. Domestic production of these formulations is limited, leading to a reliance on imports to meet the country's healthcare needs.

Tanzania applies a 0% import duty on pharmaceutical products classified under HS code 30049099, which includes finished dosage forms containing amino acids. This exemption aligns with the East African Community (EAC) Common External Tariff, which sets a 0% duty rate for medicines. Additionally, imports are subject to a 2% Railways Development Levy (RDL) and a 0.6% Destination Inspection Fee, calculated on the Free on Board (FOB) value. Tanzania is a member of the Southern African Development Community (SADC) and the EAC, allowing for preferential or nil customs duty rates for goods originating from member states, provided they meet the Rules of Origin criteria. However, there is no specific Free Trade Agreement (FTA) between Tanzania and India affecting pharmaceutical tariffs.

India is the primary supplier of finished pharmaceutical formulations containing amino acids to Tanzania, with exports totaling $3.7 million in 2024. Other major supplying countries include China and various European Union (EU) member states. India's share of Tanzania's total imports of these formulations is significant, reflecting its competitive pricing and established trade relations. Indian pharmaceutical products are generally priced lower than those from the EU, offering cost advantages to Tanzanian importers. Chinese products also compete on price, but India's established presence and compliance with international quality standards provide a competitive edge in the Tanzanian market.

India's pharmaceutical industry is a global leader in generic drug production, supplying 20% of the world's generic medicines as of 2024. The country has surpassed the United States in the number of FDA-registered manufacturing sites, boasting 752 FDA-approved, 2,050 WHO-GMP-certified, and 286 EDQM-approved facilities. This extensive infrastructure enables large-scale production of finished dosage forms, including tablets, capsules, and syrups containing Amino. India's cost-effective manufacturing processes, supported by government incentives like the Production-Linked Incentive (PLI) scheme, contribute to competitive pricing for these formulations. The country's commitment to quality is evident in its compliance with international standards, making it a preferred source for Amino formulations globally.

India's Amino formulation exports are competitively priced compared to those from China and the European Union. The country's cost-efficient production methods and economies of scale result in lower price per unit for finished dosage forms. Quality perception is high, with Indian manufacturers adhering to stringent regulatory standards, including FDA and WHO-GMP certifications. In contrast, while the EU offers high-quality branded generics, their higher production costs lead to more expensive formulations. China's generic formulations are cost-competitive but may face challenges in regulatory acceptance and quality perception in markets like Tanzania. India's established track record of reliable supply and regulatory compliance makes it a favorable choice for Tanzanian buyers seeking Amino formulations.

The India-Tanzania supply chain for Amino formulations is robust, supported by India's substantial manufacturing capacity. With over 500 active pharmaceutical ingredient producers and numerous finished dosage form manufacturers, India ensures consistent supply. The country's facilities are equipped with advanced packaging and cold chain capabilities, essential for maintaining product integrity during transit. Recent years have seen minimal supply disruptions, reflecting the reliability of Indian manufacturers. Their strong regulatory compliance track record, evidenced by a significant number of FDA and WHO-GMP certifications, further assures quality and consistency. While no significant capacity constraints have been reported, leading manufacturers continue to invest in expansion plans to meet growing global demand.

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a steady flow of Amino formulations.

• Negotiate Favorable Minimum Order Quantities (MOQs): Understand and negotiate MOQs that align with your demand to optimize inventory levels and reduce holding costs.

• Establish Clear Payment Terms: Familiarize yourself with common payment practices in India-Tanzania pharmaceutical trade, such as letters of credit or advance payments, to build trust and ensure smooth transactions.

• Conduct Thorough Supplier Qualification: Assess potential suppliers' regulatory certifications, manufacturing capabilities, and quality control measures to ensure compliance with international standards.

• Monitor Regulatory Compliance: Regularly review suppliers' adherence to regulatory requirements to maintain product quality and avoid potential legal issues.

Cost Estimates and Timeline:

• Audit Visits to India:
• Cost: Approximately $5,000 to $10,000 USD per audit, including travel, accommodation, and professional fees.
• Timeline: Planning and execution typically require 4 to 6 weeks, depending on scheduling and travel arrangements.

By adhering to this comprehensive supplier qualification process, Tanzanian companies can ensure the procurement of high-quality Amino formulations from reputable Indian manufacturers, safeguarding public health and maintaining regulatory compliance.